PL2799428T3 - Antagoniści glukagonu - Google Patents

Antagoniści glukagonu

Info

Publication number: PL2799428T3
Authority: PL; Poland
Prior art keywords: glucagon antagonists; glucagon; antagonists
Prior art date: 2008-08-13

Application number

PL14179199T

Other languages

English (en)

Inventor

Jorge E. Gomez-Galeno

Scott J. Hecker

Qun Dang

Mali Venkat Reddy

Zhili Sun

Matthew P. Grote

Thanh Huu Nguyen

Robert Huerta Lemus

Haiqing Li

Original Assignee

Metabasis Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-13

Filing date

2009-08-13

Publication date

2017-05-31

2009-08-13 Application filed by Metabasis Therapeutics, Inc. filed Critical Metabasis Therapeutics, Inc.

2017-05-31 Publication of PL2799428T3 publication Critical patent/PL2799428T3/pl

Links

102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
- C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pain & Pain Management (AREA)

PL14179199T 2008-08-13 2009-08-13 Antagoniści glukagonu PL2799428T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8869708P	2008-08-13	2008-08-13

Publications (1)

Publication Number	Publication Date
PL2799428T3 true PL2799428T3 (pl)	2017-05-31

Family

ID=41350634

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14179199T PL2799428T3 (pl)	2008-08-13	2009-08-13	Antagoniści glukagonu

Country Status (13)

Country	Link
US (4)	US8907103B2 (pl)
EP (3)	EP2326618B1 (pl)
JP (5)	JP5684126B2 (pl)
KR (2)	KR101599089B1 (pl)
CN (2)	CN102292316B (pl)
BR (1)	BRPI0918004B8 (pl)
CA (2)	CA2966273C (pl)
DK (1)	DK2799428T3 (pl)
ES (3)	ES2615481T3 (pl)
MX (1)	MX2011001708A (pl)
PL (1)	PL2799428T3 (pl)
PT (1)	PT2799428T (pl)
WO (1)	WO2010019830A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5033634A (en) *	1989-04-03	1991-07-23	The Procter & Gamble Company	Child resistant container for storing hazardous materials
KR20200123866A (ko)	2007-02-09	2020-10-30	메타베이시스 테라퓨틱스, 인크.	글루카곤 수용체의 길항제
PT2799428T (pt)	2008-08-13	2017-02-17	Metabasis Therapeutics Inc	Antagonistas de glicagina
NZ611529A (en)	2010-12-23	2015-06-26	Pfizer	Glucagon receptor modulators
WO2012107850A1 (en)	2011-02-08	2012-08-16	Pfizer Inc.	Glucagon receptor modulator
US8927577B2 (en)	2011-07-22	2015-01-06	Pfizer Inc.	Quinolinyl glucagon receptor modulators
WO2015191900A1 (en) *	2014-06-12	2015-12-17	Ligand Pharmaceuticals, Inc.	Glucagon antagonists
CN106336387A (zh) *	2015-07-10	2017-01-18	浙江海正药业股份有限公司	酰胺类衍生物、其制备方法及其在医药上的用途
US20170143673A1 (en) *	2015-11-24	2017-05-25	Remd Biotherapeutics, Inc.	Methods For Treating Heart Failure Using Glucagon Receptor Antagonists
WO2018035172A1 (en) *	2016-08-17	2018-02-22	Ligand Pharmaceuticals, Inc.	Glucagon receptor antagonists
KR102378883B1 (ko) *	2017-01-24	2022-03-25	알파라 컴퍼니 리미티드	아미드 화합물 및 그 용도
WO2019160940A1 (en)	2018-02-13	2019-08-22	Ligand Pharmaceuticals Incorporated	Glucagon receptor antagonists
KR102176621B1 (ko)	2018-08-21	2020-11-10	가천대학교 산학협력단	페닐피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3524846A (en)	1967-06-02	1970-08-18	Syntex Corp	Process for the didealkylation of phosphonate esters
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5322951B2 (pl)	1974-06-05	1978-07-12
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US4968788A (en)	1986-04-04	1990-11-06	Board Of Regents, The University Of Texas System	Biologically reversible phosphate and phosphonate protective gruops
US5091552A (en)	1986-06-30	1992-02-25	Board Of Regents, The University Of Texas System	Novel antitumor aldophosphamide analogs
JPH0738070B2 (ja)	1986-07-25	1995-04-26	富士写真フイルム株式会社	ハロゲン化銀写真感光材料
DE3860351D1 (de)	1987-03-09	1990-08-30	Eastman Kodak Co	Photographische silberhalogenidmaterialien und verfahren, das einen pyrazoloazolkuppler enthaelt.
JPH081079B2 (ja)	1987-10-12	1996-01-10	大和ハウス工業株式会社	複数階の構造物
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
EP0533833B1 (en)	1990-06-13	1995-12-20	GLAZIER, Arnold	Phosphorous produgs
US5157027A (en)	1991-05-13	1992-10-20	E. R. Squibb & Sons, Inc.	Bisphosphonate squalene synthetase inhibitors and method
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH05322951A (ja)	1992-05-26	1993-12-07	Toshiba Corp	トリップシーケンスログ装置
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
ATE199906T1 (de)	1993-06-29	2001-04-15	Mitsubishi Chem Corp	Phosphonat-nukleotid ester-derivate
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5780058A (en)	1995-07-21	1998-07-14	Alza Corporation	Oral delivery of discrete units
US6132420A (en)	1996-02-02	2000-10-17	Alza Corporation	Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
JPH09241284A (ja)	1996-03-08	1997-09-16	Koji Yamashita	新規なオキシアザホスホリン誘導体
MY125849A (en)	1997-07-25	2006-08-30	Alza Corp	Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
JPH1197740A (ja)	1997-09-19	1999-04-09	Showa Denko Kk	ＧａＰ発光ダイオード用エピタキシャルウェーハおよびＧａＰ発光ダイオード
AU1623099A (en)	1997-12-22	1999-07-12	Alza Corporation	Rate controlling membranes for controlled drug delivery devices
WO1999033446A1 (en)	1997-12-29	1999-07-08	Alza Corporation	Osmotic delivery system with membrane plug retention mechanism
AU1937099A (en)	1997-12-31	1999-07-19	Alza Corporation	Osmotic drug delivery monitoring system and method
US6245357B1 (en)	1998-03-06	2001-06-12	Alza Corporation	Extended release dosage form
US6365185B1 (en)	1998-03-26	2002-04-02	University Of Cincinnati	Self-destructing, controlled release peroral drug delivery system
IL142807A0 (en)	1998-11-02	2002-03-10	Alza Corp	Controlled delivery of active agents
US6375975B1 (en)	1998-12-21	2002-04-23	Generex Pharmaceuticals Incorporated	Pharmaceutical compositions for buccal and pulmonary application
US6342249B1 (en)	1998-12-23	2002-01-29	Alza Corporation	Controlled release liquid active agent formulation dosage forms
US6503949B1 (en)	1999-05-17	2003-01-07	Noro Nordisk A/S	Glucagon antagonists/inverse agonists
DE60023492T2 (de)	1999-05-17	2006-07-20	Novo Nordisk A/S	Glucagon antagonisten/inverse agonisten
CA2374947A1 (en)	1999-05-24	2000-11-30	Robert M. Scarborough	Inhibitors of factor xa
ATE329920T1 (de)	1999-09-10	2006-07-15	Novo Nordisk As	Modulatoren der protein tyrosin phosphatase (ptpases)
DE10008329A1 (de)	2000-02-23	2001-08-30	Merck Patent Gmbh	Aminosulfonylbiphenylderivate
HUP0301501A2 (hu)	2000-06-23	2003-08-28	Novo Nordisk A/S	Glükagon antaagonista/inverz agonista vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása gyógyászati készítmények előállítására
AU2002223501A1 (en)	2000-11-17	2002-05-27	Agouron Pharmaceuticals, Inc.	Glucagon antagonists/inverse agonists
US6881746B2 (en)	2001-12-03	2005-04-19	Novo Nordick A/S	Glucagon antagonists/inverse agonists
JP2005511683A (ja) *	2001-12-03	2005-04-28	ノボ　ノルディスク　アクティーゼルスカブ	新規なグルカゴンアンタゴニスト
US6762318B2 (en)	2001-12-03	2004-07-13	Novo Nordisk A/S	Glucagon antagonists
US20030212119A1 (en)	2001-12-20	2003-11-13	Jesper Lau	Novel glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en)	2001-12-20	2003-07-09	Novo Nordisk A/S	Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
EP1519723A1 (en)	2002-06-27	2005-04-06	Novo Nordisk A/S	Novel glucagon antagonists/inverse agonists
CA2508581A1 (en)	2002-12-04	2004-06-17	Merck & Co., Inc.	Spirocyclic ureas, compositions containing such compounds and methods of use
MY141521A (en)	2002-12-12	2010-05-14	Hoffmann La Roche	5-substituted-six-membered heteroaromatic glucokinase activators
US20040152750A1 (en)	2002-12-20	2004-08-05	Kodra Janos Tibor	Novel glucagon antagonists
AU2004210127B2 (en)	2003-01-27	2009-10-01	Merck Sharp & Dohme Corp.	Substituted pyrazoles, compositions containing such compounds and methods of use
US7138529B2 (en)	2003-04-16	2006-11-21	Hoffmann-La Roche Inc.	Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
CA2524436A1 (en)	2003-05-09	2004-11-25	Merck & Co., Inc.	Benzimidazoles, compositions containing such compounds and methods of use
CN1882327A (zh)	2003-11-19	2006-12-20	症变治疗公司	含磷的新的拟甲状腺素药
US20070054902A1 (en)	2003-12-02	2007-03-08	Shionogi & Co., Ltd.	Isoxazole derivatives as peroxisome proliferator-activated receptors agonists
US20070015757A1 (en)	2003-12-19	2007-01-18	Novo Nordisk A/S	Novel Glucagon Antagonists/Inverse Agonists
CA2547785A1 (en)	2003-12-19	2005-07-21	Merck & Co., Inc.	Cyclic guanidines, compositions containing such compounds and methods of use
US7989457B2 (en)	2004-05-28	2011-08-02	Eli Lilly And Company	Glucagon receptor antagonists, preparation and therapeutic uses
NZ551405A (en)	2004-06-04	2009-06-26	Merck & Co Inc	Pyrazole derivatives, compositions containing such compounds and methods of use
CN1968921B (zh)	2004-06-14	2011-11-23	伊莱利利公司	胰高血糖素受体拮抗剂、制备和治疗用途
CA2584502A1 (en)	2004-06-24	2006-01-05	Incyte Corporation	2-methylpropanamides and their use as pharmaceuticals
CN1980665A (zh)	2004-07-07	2007-06-13	默克公司	吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
WO2006014618A2 (en)	2004-07-22	2006-02-09	Merck & Co., Inc.	Substituted pyrazoles, compositions containing such compounds and methods of use
ES2332470T3 (es)	2005-02-11	2010-02-05	Eli Lilly And Company	Derivados de tiofeno sustituidos como antagonistas del receptor de glucagon, preparacion y usos terapeuticos.
US8318760B2 (en)	2005-03-21	2012-11-27	Merck Sharp & Dohme Corp.	Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
JP2008534593A (ja)	2005-03-30	2008-08-28	メルクエンドカムパニーインコーポレーテッド	グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法
KR100738004B1 (ko)	2005-05-23	2007-07-13	(주)주빅스테크놀러지	하이브리드 ｐ2ｐ 네트워크 지능형 분산 컴파일러 시스템및 그 방법과 상기 방법을 실현시키기 위한 프로그램을기록한 컴퓨터로 읽을 수 있는 기록매체
CN101300232A (zh)	2005-07-26	2008-11-05	默克公司	合成取代的吡唑的方法
TW200745031A (en)	2005-10-13	2007-12-16	Merck & Co Inc	Acyl indoles, compositions containing such compounds and methods of use
ES2393757T3 (es)	2005-11-17	2012-12-27	Eli Lilly & Company	Antagonistas de receptor de glucagón, preparación y usos terapéuticos
WO2007106181A2 (en)	2005-11-17	2007-09-20	Eli Lilly And Company	Glucagon receptor antagonists, preparation and therapeutic uses
WO2007114855A2 (en)	2005-11-18	2007-10-11	Eli Lilly And Company	Glucagon receptor antagonists, preparation and therapeutic uses
CN101312723B (zh)	2005-11-22	2012-01-11	伊莱利利公司	胰高血糖素受体拮抗剂、制备和治疗用途
ATE459619T1 (de)	2005-11-23	2010-03-15	Lilly Co Eli	Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
US7989472B2 (en)	2006-03-23	2011-08-02	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7935713B2 (en)	2006-05-16	2011-05-03	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7512570B2 (en)	2006-05-30	2009-03-31	Zaracom Technologies Inc.	Artificial intelligence analyzer and generator
JP5258563B2 (ja)	2006-06-29	2013-08-07	日産化学工業株式会社	αアミノ酸誘導体及びそれを有効成分として含む医薬
TW200821284A (en)	2006-10-03	2008-05-16	Merck & Co Inc	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN101595089A (zh)	2006-12-02	2009-12-02	财团法人首尔大学校产学协力财团	作为ppar配体的芳基化合物及其用途
KR20200123866A (ko)	2007-02-09	2020-10-30	메타베이시스 테라퓨틱스, 인크.	글루카곤 수용체의 길항제
PT2799428T (pt)	2008-08-13	2017-02-17	Metabasis Therapeutics Inc	Antagonistas de glicagina
CN103813794A (zh)	2011-07-18	2014-05-21	拓凯制药公司	用于治疗前列腺癌的新型组合物及方法
US8869708B1 (en)	2011-08-26	2014-10-28	Daniel P. Meyer	Model railroad flashing rear end device
WO2015191900A1 (en)	2014-06-12	2015-12-17	Ligand Pharmaceuticals, Inc.	Glucagon antagonists
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
JP2017051900A (ja)	2015-09-08	2017-03-16	国立大学法人横浜国立大学	触媒とその製造方法
CN205117265U (zh)	2015-11-19	2016-03-30	北京美高科技发展有限公司	电缆式电液控制割管工具

2009
- 2009-08-13 PT PT141791996T patent/PT2799428T/pt unknown
- 2009-08-13 CN CN200980141324.4A patent/CN102292316B/zh not_active Expired - Fee Related
- 2009-08-13 ES ES14179199.6T patent/ES2615481T3/es active Active
- 2009-08-13 PL PL14179199T patent/PL2799428T3/pl unknown
- 2009-08-13 EP EP09791510.2A patent/EP2326618B1/en not_active Not-in-force
- 2009-08-13 EP EP16198552.8A patent/EP3153501B1/en not_active Not-in-force
- 2009-08-13 JP JP2011523184A patent/JP5684126B2/ja active Active
- 2009-08-13 CN CN201510257808.2A patent/CN104803891B/zh active Active
- 2009-08-13 US US13/058,604 patent/US8907103B2/en active Active
- 2009-08-13 WO PCT/US2009/053795 patent/WO2010019830A1/en not_active Ceased
- 2009-08-13 EP EP14179199.6A patent/EP2799428B1/en active Active
- 2009-08-13 CA CA2966273A patent/CA2966273C/en not_active Expired - Fee Related
- 2009-08-13 BR BRPI0918004A patent/BRPI0918004B8/pt not_active IP Right Cessation
- 2009-08-13 KR KR1020117005737A patent/KR101599089B1/ko not_active Expired - Fee Related
- 2009-08-13 DK DK14179199.6T patent/DK2799428T3/da active
- 2009-08-13 KR KR1020157027964A patent/KR101634515B1/ko not_active Expired - Fee Related
- 2009-08-13 MX MX2011001708A patent/MX2011001708A/es active IP Right Grant
- 2009-08-13 ES ES09791510.2T patent/ES2527670T3/es active Active
- 2009-08-13 ES ES16198552T patent/ES2714207T3/es active Active
- 2009-08-13 CA CA2770298A patent/CA2770298C/en not_active Expired - Fee Related
2014
- 2014-11-26 US US14/555,503 patent/US9783494B2/en active Active
2015
- 2015-01-14 JP JP2015005005A patent/JP2015129133A/ja active Pending
2016
- 2016-12-26 JP JP2016251460A patent/JP6309076B2/ja active Active
2017
- 2017-09-29 US US15/721,556 patent/US10221130B2/en active Active
2018
- 2018-01-19 JP JP2018006976A patent/JP6490843B2/ja active Active
2019
- 2019-02-27 JP JP2019033889A patent/JP2019112427A/ja active Pending
- 2019-02-28 US US16/289,241 patent/US11352321B2/en active Active

Also Published As

Publication number	Publication date
JP5684126B2 (ja)	2015-03-11
KR20150118203A (ko)	2015-10-21
CA2770298C (en)	2017-06-20
CN104803891A (zh)	2015-07-29
US20150087680A1 (en)	2015-03-26
US8907103B2 (en)	2014-12-09
CA2966273A1 (en)	2010-02-18
EP2326618A1 (en)	2011-06-01
EP2799428A2 (en)	2014-11-05
JP6490843B2 (ja)	2019-03-27
BRPI0918004B8 (pt)	2021-05-25
US20130030029A1 (en)	2013-01-31
US11352321B2 (en)	2022-06-07
JP2017101039A (ja)	2017-06-08
JP2012500212A (ja)	2012-01-05
EP3153501B1 (en)	2018-11-28
KR101634515B1 (ko)	2016-06-28
EP3153501A1 (en)	2017-04-12
PT2799428T (pt)	2017-02-17
ES2527670T3 (es)	2015-01-28
BRPI0918004B1 (pt)	2019-08-13
WO2010019830A1 (en)	2010-02-18
CN102292316B (zh)	2015-07-01
CN104803891B (zh)	2017-10-20
JP2019112427A (ja)	2019-07-11
EP2799428A3 (en)	2014-12-17
BRPI0918004A2 (pt)	2015-11-17
HK1203481A1 (en)	2015-10-30
JP2018083834A (ja)	2018-05-31
US20190330144A1 (en)	2019-10-31
US9783494B2 (en)	2017-10-10
US20180022695A1 (en)	2018-01-25
EP2326618B1 (en)	2014-10-15
CA2966273C (en)	2019-08-27
JP2015129133A (ja)	2015-07-16
US10221130B2 (en)	2019-03-05
ES2714207T3 (es)	2019-05-27
MX2011001708A (es)	2011-04-26
EP2799428B1 (en)	2016-11-16
CA2770298A1 (en)	2010-02-18
DK2799428T3 (da)	2017-02-20
ES2615481T3 (es)	2017-06-07
JP6309076B2 (ja)	2018-04-11
CN102292316A (zh)	2011-12-21
KR20110042357A (ko)	2011-04-26
KR101599089B1 (ko)	2016-03-02

Publication	Publication Date	Title
IL213479A0 (en)	2011-07-31	Glucagon analogues
ZA201104593B (en)	2015-01-28	Glucagon analogues
IL213477A0 (en)	2011-07-31	Glucagon analogues
ZA201104591B (en)	2014-11-26	Glucagon analogues
TWI367207B (en)	2012-07-01	Substituted pyrrolidine-2-carboxamides
PT2799428T (pt)	2017-02-17	Antagonistas de glicagina
GB2474194B (en)	2012-12-05	Scaffolding
ZA200906812B (en)	2010-12-29	Crig antagonists
EP2312947A4 (en)	2012-04-04	TRPV4 Antagonist
GB0809344D0 (en)	2008-07-02	Palringo local
GB0902610D0 (en)	2009-04-01	Materials
IL208281A0 (en)	2010-12-30	Substituted cyclohexyldiamines
IL209175A0 (en)	2011-01-31	Substituted qunazolines
GB0911055D0 (en)	2009-08-12	Handrails
ZA201005986B (en)	2011-04-28	Novel heterocycles
GB201000798D0 (en)	2010-03-03	Poly-TLR antagonists
GB0809659D0 (en)	2008-07-02	Polypeptides
HU0800039V0 (en)	2008-04-28	Construction set
SI2340021T1 (sl)	2013-02-28	Substituirani pirolidin-2-karboksamidi
GB0808387D0 (en)	2008-06-18	Glp-1
GB0808400D0 (en)	2008-06-18	Somatostatin
GB0814373D0 (en)	2008-09-10	Tissue-adhesive materials
GB0812733D0 (en)	2008-08-20	Self-coalescing materials
GB0711673D0 (en)	2007-07-25	Glucagon analogues
PL385623A1 (pl)	2009-11-23	Zabezpiecznik